Can Buying Exelixis Stock Still Make You Rich?
What were you doing on Friday, Jan. 2, 2015? It's OK if you don't remember. I certainly can't.
But there were some investors who did something on that date who probably recall it with a smile. Anyone who bought shares of Exelixis (NASDAQ: EXEL) at the beginning of 2015 and held on to the stock are now sitting on a return of 1,560%. A $10,000 investment in the biotech less than three years ago would now be worth $166,000.
Exelixis has been one of the hottest biotech stocks in recent years. But can buying this stock still make you rich? It just might.
Source: Fool.com
Pfizer Inc. Aktie
25,77 €
0,14 %
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.
